Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy

Clinical Infectious Diseases

Volumn 47, Issue 8, 2008, Pages 1105-1108

  Wohl, David A ^a   Waters, David ^b   Simpson Jr , Ross J ^a   Richard, Susan ^a   Schnell, Amanda ^b   Napravnik, Sonia ^a   Keys, Jessica ^a   Eron Jr , J Joseph ^a   Hsue, Priscilla ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EMTRICITABINE; EZETIMIBE; LAMIVUDINE PLUS ZIDOVUDINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TENOFOVIR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HEADACHE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPROTEIN BLOOD LEVEL; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; VIRUS INFECTION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AZETIDINES; CHOLESTEROL, LDL; FEMALE; HIV INFECTIONS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PLACEBOS;

EID: 53349101854     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/592116     Document Type: Article

References (20)

1. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
2. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl JMed 2007; 356:1723-35.
3. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with HIV disease. J Clin Endocrinol Metab 2007; 92:2506-12.
4. - Northern Californians: 1994-2006 [abstract 807]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles, CA). 2007.
5. Iloeje UH, Yuan Y, L'Italien G, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6:37-44.
6. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006; 368:476-82.
7. Haubrich RH, Riddler S, DiRienzo G, et al.; and the AIDS Clinical Trials Group 5142 Study Team. Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection [abstract 38]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections (Los Angeles, CA). 2007.
8. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
9. Gallant JE, DeJesus E, Arribas JR, et al.; for the Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-60.
10. Malan N, Krantz E, David N, et al.; the 089 Study Group. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089 [abstract 107LB]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver, CO). 2006.
11. Walmsley S, Bredeek U, Avihingsanon A, et al. Evaluation of the impact of highly active antiretroviral therapy (HAART) on lipid profiles - data from the 24-week interim analysis of the Gemini Study: saquinavir/r (SQV/r) BID vs. lopinavir/r (LPV/r) BID plus emtricitabine/tenofovir (FTC/TDF) QD in ARV-naive HIV-1-infected patients [abstract TUPEB069]. In: Program and abstracts of the 4th International AIDS Society Conference (Sydney, Australia). 2007.
12. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004; 1:e19.
13. Lichtenstein K, Armon C, Buchacz K, Moorman A, Wood K, Brooks J; the HIV Outpatient Study Group. Analysis of cardiovascular risk factors in the HIV outpatient study cohort [abstract 735]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver, CO). 2006.
14. Zetia [package insert]. North Wales, PA: Merck/Schering-Plough, 2007.
15. Negredo E, Moltó J, Puig J, et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 2006; 20:2159-64.
16. Coll B, Aragonés G, Parra S, Alonso-Villaverde C, Masana L. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 2006; 20:1675-7.
17. Bennett MT, Johns KW, Bondy GP. Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV. Lipids Health Dis 2007; 6:15.
18. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.
19. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004; 44:720-32.
20. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358:1431-43.